A method for determining whether bacteria in a sample obtained from a subject at a point of care in a clinical setting is susceptible to an antibiotic, within a time period associated with a point of care, the method comprising: (i) applying, at a first time, to a portion of the sample, a first reagent to create a first test sample from which non-bacteria based background adenosine triphosphate has been removed by the first reagent; wherein the first reagent comprises a detergent selected from cetalkonium chloride, hexadecyltrimethyl ammonium bromide (CTAB), chlorhexidine diacetate, benzethonium chloride, sodium dodecyl sulfate, Tween 20; and Tween 80; and a hydrolytic enzyme selected from adenylate kinase, apyrase, ATP synthase, ATPase and urea amidohydrolase; (ii) incubating the first test sample for a first time period; (iii) applying a second reagent to the first test sample to release ATP from bacterial cells when the first test sample includes bacterial cells; wherein the second reagent comprises luciferase, luciferin, and a detergent selected from chlorhexidine di-gluconate, benzethonium chloride, hexadecyltrimethyl ammonium bromide (CTAB), Tween 20 and Tween 80, (iv) measuring a bioluminescent signal from the first test sample based on released ATP; (v) determining whether the sample includes the bacterial infection by comparing the the bioluminescent signal to a first threshold of 30000 to 5000000 RLUs; (vi) applying, to at least a portion of the sample, said first reagent and a culture medium to create a second test sample and a third test sample, from which non-bacteria based background ATP has been removed by said first reagent; (vii) applying a first antibiotic to the third test sample; (viii) incubating the second test sample and the third test sample for a second time period and at a first temperature; (ix) applying said second reagent to the second test sample and the third test sample at the end of the second time period; (x) measuring a first bioluminescent signal from the second test sample based on released ATP and a second bioluminescent signal from the third test sample based on released ATP; (xi) determining a difference between the first bioluminescent signal and the second bioluminescent signal; and determining, at a third time, that the bacterial infection is susceptible to the first antibiotic when the second bioluminescent signal is at least 20% lower than the first bioluminescent signal, a difference between the first time and the third time being less than the time period associated with the point of care visit, said time period being 60 mins. (i) applying, at a first time, to a portion of the sample, a first reagent to create a first test sample from which non-bacteria based background adenosine triphosphate has been removed by the first reagent; wherein the first reagent comprises a detergent selected from cetalkonium chloride, hexadecyltrimethyl ammonium bromide (CTAB), chlorhexidine diacetate, benzethonium chloride, sodium dodecyl sulfate, Tween 20; and Tween 80; and a hydrolytic enzyme selected from adenylate kinase, apyrase, ATP synthase, ATPase and urea amidohydrolase; (ii) incubating the first test sample for a first time period; (iii) applying a second reagent to the first test sample to release ATP from bacterial cells when the first test sample includes bacterial cells; wherein the second reagent comprises luciferase, luciferin, and a detergent selected from chlorhexidine di-gluconate, benzethonium chloride, hexadecyltrimethyl ammonium bromide (CTAB), Tween 20 and Tween 80, (iv) measuring a bioluminescent signal from the first test sample based on released ATP; (v) determining whether the sample includes the bacterial infection by comparing the the bioluminescent signal to a first threshold of 30000 to 5000000 RLUs; (vi) applying, to at least a portion of the sample, said first reagent and a culture medium to create a second test sample and a third test sample, from which non-bacteria based background ATP has been removed by said first reagent; (vii) applying a first antibiotic to the third test sample; (viii) incubating the second test sample and the third test sample for a second time period and at a first temperature; (ix) applying said second reagent to the second test sample and the third test sample at the end of the second time period; (x) measuring a first bioluminescent signal from the second test sample based on released ATP and a second bioluminescent signal from the third test sample based on released ATP; (xi) determining a difference between the first bioluminescent signal and the second bioluminescent signal; and determining, at a third time, that the bacterial infection is susceptible to the first antibiotic when the second bioluminescent signal is at least 20% lower than the first bioluminescent signal,